Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals

$5,000.00 – $10,000.00

SKU: 23-022 Categories: , , , , , , Tags: , , , , , Pages: 261

Description

This report, Kalorama’s Cell and Gene Deals and Market Analysis, tracks the dealmaking and market opportunity for cell and gene therapy companies.  A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama’s latest report finds that the volume of deals between companies and other funding entities involving CGT is up, and companies have continued to receive large amounts of investment despite a decline from 2021 levels of investment.

Kalorama’s CGT deals amounted to a staggering $40 billion in 2022.

While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years.  Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area.  There are now many approved therapies with proven track records.

As the new tools have lowered the barriers to entry for the industry, over 1,500 companies have been created or have become involved.

The following is just some of the information in this report:

  • Most Active Deal-Making Companies
  • Deals per Month, April 2021-March 2023
  • Deals by Type – Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
  • Venture Capital and Private Funding Deals by Month, January 2021-March 2023 (Total count)
  • Regional Venture Capital/Private Funding Shares [North America, Europe, APAC, Rest of World] (%)
  • Total Number of Mergers and Acquisitions, By Month
  • Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q1 2023] ($M)
  • List of M&As [Company 1, Company 2, Details, Amount, w/Milestones, Date]
  • Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)
  • Most Active Companies in Acquisition/Merger/ Strategic Investment
  • Most Active Companies in Overall Deals, Collaborations
  • Estimated Market Forecasts for Cell and Gene Therapies by Type (Gene Therapy, Cell Therapy)
  • Estimated Market Forecasts by Region (North America, EU, APAC, Other)
  • Estimated Market Forecasts for CGT by Disease Category (Oncology, Other)

No report published by a major market research publisher has tackled the Cell and Gene Therapy dealmaking space as it exists in 2023 in a more comprehensive fashion.  As Cell and Gene Therapy is a highly competitive marketplace, hundreds of companies are referenced in this report.

Table of Contents

Chapter 1: Executive Summary

Introduction
$40.2 Billion in Funding During 2022
  • Figure 1-1: Total Deals per Month, April 2021-March 2023 (Total count)
  • Figure 1-2: Total Deals per Month by Type, Apr 2021-Mar 2023 [VC/ Private, IPO/FPO/SPAC; and All Other Deals] (Total count)
Quarterly Funding Amounts
  • Table 1-1: Total Quarterly Funding, by Type, Q1 2021-Q4 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
  • Table 1-2: Total Quarterly Funding, by Type, Q1 2022-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
  • Figure 1-3: Total Quarterly Funding, Q1 2021- Q1 2023 ($M)
  • Figure 1-4: Total Quarterly Funding, by Type, Q1 2021-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Quarterly Funding Category Shares, Q1 2021 Through Q1 2023
  • Table 1-3: Total Quarterly Funding Share, by Type, 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Table 1-4: Total Quarterly Funding Share, by Type, Q1 2022-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Figure 1-5: Q1 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Figure 1-6: Q2 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Figure 1-7: Q3 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Figure 1-8: Q4 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Figure 1-9: Q1 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)

Quarterly Deal Counts by Category, Q1 2021 – Q1 2023

  • Table 1-5: Quarterly Count of Deals, By 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution,  Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
  • Table 1-6: Quarterly Count of Deals, by Quarter Q1 2022-Q1 2023, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)

Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy

  • Figure 1-10: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)

A Look at Less Frequent CGT Deal Types

  • Figure 1-11: Lower Frequency Deal Types, by Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
  • Figure 1-12: Merger/ Acquisition Amount, by Quarter [Q1 2021 – Q1 2023] ($M)
  • Figure 1-13: Venture Capital/Private Funding Round Amount, by Quarter [January 2021-January 2022] ($M)
  • Figure 1-14: IPO/FPO Amount, by Quarter [Q1 2021-Q1 2023] ($M)
  • Figure 1-15: SPAC Portion Amount, by Year and Q1 2023 ($M)
Synopsis of Most Active Deal-Making Companies
  • Table 1-7: Most Active Companies’ Deal-Making Rankings, by Category, 2021-Q1 2023 (Rank)
  • Table 1-8: Most Active Companies in Overall Deals, Collaborations
  • Figure 1-16: Most Active Companies in Overall Deals, Collaborations

 

Chapter 2: Venture Capital & Private Funding

VC/Private Funding in Flux
  • Figure 2-1: Total Number of VC/ Private Funding Deals by Month, January 2021-March 2023 (Total count)
  • Figure 2-2: Average VC/ Private Funding Round Amount, By Quarter Q1 2021-Q1 2023 ($M)
  • Table 2-1: Regional Venture Capital/Private Funding, by Quarter Q1 2021-Q1 2023,  [North America, Europe, APAC, Rest of World] ($M) (%)
  • Figure 2-3: Quarterly Venture Capital/Private Total Funding, Q1 2021- Q1 2023, by Region [North America, Europe, APAC, Rest of World] ($M)
  • Table 2-2: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021-Q1 2023,  [North America, Europe, APAC, Rest of World] (%)
  • Figure 2-4: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021 Q1 2023,  [North America, Europe, APAC, Rest of World] (%)
  • Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter [Q1 2021-Q1 2023] ($M)
  • Table 2-3: Venture Capital/Private Fundraising Deals, Q1 2023
  • Table 2-4: Venture Capital/Private Fundraising Deals, Q4 2022
  • Table 2-5: Venture Capital/Private, Q3 2022
  • Table 2-6: Venture Capital/Private Fundraising Deals, Q2 2022
  • Table 2-7: Venture Capital/Private Fundraising Deals, Q1 2022

 

Chapter 3: Strategic Investments

Strategic Investments in Cell and Gene Therapy
  • Figure 3-1: Total Number of Strategic Investments, By Quarter [Q1 2021-Q1 2023] (Total count)
  • Figure 3-2: Average Strategic Investment Amount, By Quarter [Q1 2021-Q1 2023] ($M)
  • Figure 3-3: Total Strategic Investments, By Quarter [Q1 2021-Q1 2023] ($M)
  • Table 3-1: Strategic Investment Total Amounts, Counts, and Averages, by Quarter, Q1 2021 Q1 2023,  ($M)
  • Table 3-2: Strategic Investments, January 2021-April 2023
Most Active Companies
  • Table 3-3: Most Active in Acquisition/Merger/ Strategic Investment
  • Figure 3-4: Most Active in Acquisition/Merger/ Strategic Investment

 

Chapter 4: IPOs, FPOs, & SPACs

North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
  • Figure 4-1: Total Number of IPOs/ FPOs, By Month [Jan 2021-Mar 2023] (Total count)
  • Figure 4-2: Average IPO/ FPO Proceeds, By Quarter [Q1 2021-Q1 2023] ($M)
  • Table 4-1: Quarterly IPO/ FPO Total Funding, Q1 2021 Q1 2023,  by Region [North America, Europe, APAC] ($M)
  • Figure 4-3: Total IPO/ FPO Funding, By Quarter, by Region [Q1 2021-Q1 2023] ($M)
  • Table 4-2: Regional IPO/ FPO Funding Shares, by Quarter, Q1 2021 Q1 2023,  [North America, Europe, APAC] (%)
  • Figure 4-4: Regional IPO/FPO Funding Shares, By Quarter, Q1 2021 Q1 2023 [North America, APAC, and Europe) (%)
  • Figure 4-5: IPO/FPO Amounts, By Quarter [Q1 2021-Q1 2023] ($M)
  • Table 4-3: Quarterly SPAC Funding Portion, Q1 2021-Q1 2023 ($M)
  • Figure 4-6: Quarterly SPAC Funding Portion Total and Average, Q1 2021-Q1 2023 ($M)
  • Table 4-4: IPO/FPO Deals, Q1 2023
  • Table 4-5: IPO/FPO Deals, Q4 2022
  • Table 4-6: IPO/FPO Deals, Q3 2022
  • Table 4-7: IPO/FPO Deals, Q2 2022
  • Table 4-8: IPO/FPO Deals, Q1 2022
  • Table 4-9: SPAC Portion, January 2021-Mar 2023 ($M)
  • Figure 4-7: SPAC Portion Amount, by Year, ’21, ’22, Q1 2023 ($M)

 

Chapter 5: Mergers & Acquisitions (M&A)

Growing Numbers of M&A, Despite Lower Average Value
  • Figure 5-1: Total Number of Mergers and Acquisitions, By Month [Jan 2021-Mar 2023] (Total Count)
  • Figure 5-2: Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q1 2023] ($M)
  • Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q1 2023 ($M) (Total count)
  • Figure 5-3: Merger/ Acquisition Transactions Global Total, By Quarter [Q1 2022- Q1 2023] ($M)
  • Figure 5-4: Merger/ Acquisition Amounts, by Quarter [Q1 2021- Q1 2023] ($M)
  • Table 5-2: Mergers and Acquisitions Announcements, Q1 2023 ($M)
  • Table 5-3: Mergers and Acquisitions, Q4 2022 ($M)
  • Table 5-4: Mergers and Acquisitions, Q3 2022 ($M)
  • Table 5-5: Mergers and Acquisitions, Q2 2022 ($M)
  • Table 5-6: Mergers and Acquisitions, Q1 2022 ($M)
Most Active Companies
  • Table 5-7: Most Active in Acquisition/Merger/Strategic Investment
  • Figure 5-5: Most Active in Acquisition/Merger/ Strategic Investment

 

Chapter 6: Technology/Research/Strategic Collaborations

CGT Market Sees a Broad Variety of Collaborations
  • Figure 6-1: Total Number of Tech/ Research/ Strategic Collaborations, By Month [Jan 2021-Mar 2023] (Total count)
  • Figure 6-2: Total Number of Collaborations with Upfront and/or Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
  • Table 6-1: Collaboration Upfront and Future/ Milestone Payments, Counts, Averages, Q1 2021-Q1 2023 ($M) (Total count)
  • Figure 6-3: Average Collaboration Upfront Payment, By Quarter [Q1 2021-Q1 2023] ($M)
  • Figure 6-4: Total Collaboration Upfront Payments, By Quarter [Q1 2021-Q1 2023] ($M)
  • Figure 6-5: Average Collaboration Future/ Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
  • Figure 6-6: Total Collaboration Future/ Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
  • Table 6-2: Technology/Research/Strategic Collaboration Deals, January 2022–April 2023
Most Active Companies
  • Table 6-3: Most Active in Research/Strategic Collaborations
  • Figure 6-7: Most Active in Research/Strategic Collaborations

 

Chapter 7: Licensing

Stable Levels of Licensing in the Cell and Gene Therapy Market
  • Figure 7-1: Total Number of Licensing Deals, By Month [Jan 2021-Mar 2023] (Total count)
  • Table 7-1: Licensing Deals, January 2022-April 2023
Most Active Companies
  • Table 7-2: Most Active Companies in Licensing Deals
  • Figure 7-2: Most Active Companies in Licensing Deals

 

Chapter 8: Manufacturing and Supply Chain

Major Growth in Manufacturing and Supply Chain Management Activity in CGT
  • Figure 8-1: Total Number of Supply/ Manufacturing Deals, By Month [Jan 2021-Mar 2023] (Total count)
  • Table 8-1: Manufacturing and Supply Chain Deals, January 2022-March 2023
Most Active Companies
  • Table 8-2: Most Active Companies in Manufacturing/Supply Deals
  • Figure 8-2: Most Active Companies in Manufacturing/Supply Deals

 

Chapter 9: Public Outreach, Education, & Philanthropy

CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Education, and Philanthropy
  • Figure 9-1: Total Number of Outreach/ Philanthropy/ Education Deals, By Month [Jan 2021-Mar 2023] (Total count)
  • Table 9-1: Outreach, Education, & Philanthropy Deals, January 2022-Apr 2023

 

Chapter 10: Distribution & Co-Marketing

A Look at CGT Distribution and Co-Marketing Deals
  • Figure 10-1: Total Number of Distribution/ Co-Marketing Deals, by Month [Jan 2021-Mar 2023] (Total count)
  • Table 10-1: Distribution & Co-Marketing Deals, January 2022-Mar 2023
Most Active Companies
  • Table 10-2: Most Active Companies in Distribution/Co-Marketing Deals
  • Figure 10-2: Most Active Companies in Distribution/Co-Marketing Deals

 

Chapter 11: Other – JV, Restructuring, Termination, Spinoffs

A Look at Other Types of Deals Impacting Cell and Gene Therapy
  • Figure 11-1: Total Number of JV, Restructuring, Termination, By Month [Jan 2021-Mar 2023] (Total count)
  • Table 11-1: Restructuring, JV, Termination, Spinoffs, January 2022-April 2023

 

Chapter 12: Other – New Facilities, Expansion; Real Estate

Expansion, New Facilities and Related Announcements
  • Table 12-1: New Facilities, Expansion; Real Estate Deals, January 2022-April 2023

 

Appendix: Cell and Gene Therapy Market Assessment

Market Outlook, 2022-2032
  • Table A-1: Cell and Gene Therapy Market Revenues by Product Type, 2022 and Projected 2027 and 2032  ($ millions)
  • Figure A-1: Cell and Gene Therapy Market Revenue Share, by Product Type [Cardiovascular-Blood, Dermatological, Musculoskeletal, Neurology, Oncology, Ophthalmic, Other Conditions] (%)
Regional Market
  • Table A-2: Cell and Gene Therapy Market by Country/Region [Europe, United States, Other Countries], 2022 Projected 2027 and 2032 ($ millions)
Products on the Market
  • Table A-3: Major Cell and Gene Therapy Product Approvals, FDA
Top Companies in Cell and Gene Therapy
  • Figure A-2: Leading Companies in Cell and Gene Therapy, By Company [Amylan, Bristol Myers, Dendreon, Gilead, Novartis, Smith and Nephew, Others]

 

 

Related products

Clinical Laboratory Services Market, 8th Edition